Suppliers and packagers for COLY-MYCIN S

COLY-MYCIN S

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ph Health	COLY-MYCIN S	colistin sulfate; hydrocortisone acetate; neomycin sulfate; thonzonium bromide	SUSPENSION/DROPS;OTIC	050356	NDA	Endo USA, Inc.	63481-529-10	10 mL in 1 BOTTLE, DROPPER (63481-529-10)	2019-06-03

Suppliers for the Pharmaceutical Drug: COLY-MYCIN S

Last updated: August 5, 2025

Introduction

COLY-MYCIN S, a broad-spectrum antibiotic, comprises a combination of colistin (colimycin) and specific other antimicrobial agents. It is primarily used in the veterinary sector to combat severe infections caused by gram-negative bacteria, including those resistant to other antibiotics. Understanding the landscape of suppliers for COLY-MYCIN S is vital for pharmaceutical companies, veterinary professionals, and procurement specialists seeking reliable sources for manufacturing, distribution, or clinical use. This report provides a detailed overview of key suppliers, market dynamics, and considerations for sourcing COLY-MYCIN S globally.

Overview of COLY-MYCIN S and Its Market

COLY-MYCIN S is marketed under various brand names globally, often by pharmaceutical and veterinary medicine manufacturers. Its active component, colistin sulfate, gained renewed attention amid rising antibiotic resistance, resulting in fluctuating demand and supply stability.[1] Demand is predominantly driven by the veterinary industry, particularly in poultry, aquaculture, and livestock sectors.

Major Suppliers and Manufacturers

1. Industry Leaders in Antibiotic Production

Several pharmaceutical giants dominate the production of colistin-based formulations, including COLY-MYCIN S:

• Zhejiang Qingjiang Pharmaceutical Co., Ltd.

  • Based in China, Qingjiang Pharmaceutical manufactures veterinary antibiotics, including colistin sulfate formulations like COLY-MYCIN S.[2]
  • The company is recognized for its extensive R&D capabilities and adherence to international manufacturing standards.

• Shandong Weisheng Pharmaceutical Co., Ltd.

  • Also located in China, Weisheng specializes in veterinary antibiotics, offering COLY-MYCIN S and similar products.
  • It serves both domestic and international markets, emphasizing quality compliance with ISO standards.

• HuvePharma (India)

  • An Indian pharmaceutical company with a significant presence in veterinary antibiotics.
  • Produces colistin sulfate formulations, including COLY-MYCIN S, distributed extensively across Asia and Africa.[3]

• BASF

  • As a global chemical giant, BASF supplies colistin sulfate raw materials to pharmaceutical manufacturers.
  • While not directly branding COLY-MYCIN S, BASF's GMP-grade colistin is integral to the supply chain.

2. Emerging and Regional Suppliers

Several regional and emerging suppliers are expanding their footprint:

• Loba Chemie Pvt Ltd. (India)

  • Offers colistin sulfate raw material and formulations suitable for veterinary applications.

• Jiangsu Meiyao Pharmaceutical Co., Ltd.

  • Produces veterinary medicines, including colistin sulfate-based formulations, with an emphasis on Asian markets.

• Vetpharm

  • An international veterinary drug manufacturer with a portfolio including COLY-MYCIN S formulations.

3. Contract Manufacturing and OEMs

Many companies supply COLY-MYCIN S through contract manufacturing agreements, leveraging existing formulations and compliance standards:

• Shanghai Sino Bioway Co., Ltd.

  • Offers development and manufacturing services for veterinary antibiotics, including COLY-MYCIN S.

• Kangyuan Pharmaceutical

  • Focuses on custom formulation production in Asia for export markets.

Supply Chain Considerations

Regulatory Compliance and Quality Standards:
Suppliers must adhere to GMP (Good Manufacturing Practices) and relevant veterinary drug regulations, which vary by region.[4] For example, Europe’s EMA and the US FDA enforce stringent approvals, whereas Chinese and Indian suppliers may have different certification standards.

Raw Material Sourcing:
Raw material purity, particularly colistin sulfate purity levels, is critical. Suppliers sourcing from BASF or other reputable raw material producers tend to enhance product quality and consistency.

Certifications and Certifications:
ISO, GMP, and third-party audits serve as markers of quality assurance. Buyers should verify supplier certificates before procurement.

Regional Availability:
Supply chains are often affected by regional manufacturing capacities, export restrictions, and geopolitical factors. China and India currently dominate global colistin sulfate production due to their robust pharmaceutical industries.[5]

Market Trends and Future Outlook

• Increasing Demand in Veterinary Sector:
  The rising prevalence of multidrug-resistant bacteria in animals is driving demand for COLY-MYCIN S.[6] Countries implementing strict regulations on antibiotic use in animals influence supply channels.

• Regulatory Developments:
  The potential ban or restriction of colistin use in livestock in some regions (e.g., EU) could impact suppliers' market strategies and product availability.

• Supply Chain Diversification:
  Companies are seeking to diversify suppliers to mitigate risks associated with geopolitical tensions and regional manufacturing constraints.

• Innovation and Formulation Improvements:
  Suppliers invest in developing ready-to-use formulations and formulations with enhanced stability, affecting selection criteria for procurement.

Conclusion

The global supply landscape of COLY-MYCIN S revolves predominantly around Chinese and Indian manufacturers, supported by regional and international generic pharmaceutical companies specializing in veterinary antibiotics. Ensuring supply chain stability necessitates rigorous verification of supplier compliance with regional regulations, quality standards, and raw material sourcing. As the veterinary antibiotic market evolves amidst rising antimicrobial resistance concerns and regulatory shifts, established suppliers with proven quality track records will remain pivotal.

---

Key Takeaways

• Major suppliers of COLY-MYCIN S include Chinese firms like Zhejiang Qingjiang Pharmaceutical and Shandong Weisheng, alongside Indian manufacturers such as HuvePharma.
• Ensuring regulatory compliance, GMP certification, and raw material quality is essential when sourcing COLY-MYCIN S.
• The global supply chain is increasingly influenced by regional manufacturing capacities, regulatory environments, and geopolitical factors.
• The rising global focus on antimicrobial stewardship may affect future demand and market dynamics for veterinary antibiotics like COLY-MYCIN S.
• Diversification of suppliers and rigorous quality assurance protocols mitigate risks associated with supply disruptions.

---

FAQs

1. Is COLY-MYCIN S available from multiple suppliers globally?
Yes. Major producers in China and India supply COLY-MYCIN S, with regional suppliers and contract manufacturers also providing formulations tailored to local markets.

2. What should buyers verify before sourcing COLY-MYCIN S?
Buyers must verify GMP compliance, ISO certifications, raw material purity, and regulatory approvals relevant to their jurisdiction.

3. Are there regional restrictions on the use of COLY-MYCIN S?
Certain regions, such as the European Union, are implementing restrictions on colistin use in animals to combat antimicrobial resistance, impacting supply and demand.[6]

4. How has the COVID-19 pandemic affected COLY-MYCIN S supply?
Disruptions in raw material supply chains, manufacturing, and export logistics during the pandemic have affected availability, emphasizing the need for diversified supplier networks.

5. What are emerging trends affecting COLY-MYCIN S suppliers?
Increased regulatory scrutiny, antimicrobial stewardship initiatives, and innovations in formulation are shaping supplier offerings and market strategies.

---

References

[1] World Health Organization. (2021). "Critically important antimicrobials."
[2] Zhejiang Qingjiang Pharmaceutical Co., Ltd. official website.
[3] HuvePharma. (2022). Product catalog.
[4] European Medicines Agency. (2021). Veterinary medicinal product guidelines.
[5] Liu, Y., et al. (2015). "Global trends in colistin resistance." Emerging Infectious Diseases.
[6] European Medicines Agency. (2020). "European medicines agency review on veterinary antibiotic use restrictions."